Anne-Marie Masquelier joins Cegedim Strategic Data

Takes role of global medical research director

Cegedim Strategic Data (CSD), a French provider of integrated healthcare research, has appointed Dr Anne-Marie Masquelier as global medical research director of its medical research CRO activities worldwide.

Masquelier is a medical doctor MD with a specialisation in endocrinology and holds an MBA in marketing/management. She started her career as a medical practitioner before moving to the healthcare industry where she held various management positions in pharmaceutical, CRO and biotech companies. Most recently she was general manager of Genethon.

Masquelier will manage CSD’s established medical research teams in France, Germany, Italy, Spain and UK, China, Japan and the US. She will continue the expansion of this activity in all of the 39 countries where CSD is present.

You may also like

Regulatory

Power to the patient: The value of longitudinal data

Steve Bradley, Group Managing Director, Cegedim UK, outlines how data holds the key to better patient care
Finance

Cegedim Dendrite forms partnership with TAKE Solutions

Arrangement will enable Cegedim to expand its presence in India
Finance

Cegedim expands business in Switzerland

Acquires Swiss CRM and Direct Marketing businesses of IMS Health
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Subscribe now